B
Barry J. Ratzkin
Researcher at Amgen
Publications - 24
Citations - 3149
Barry J. Ratzkin is an academic researcher from Amgen. The author has contributed to research in topics: Neuregulin & Receptor. The author has an hindex of 16, co-authored 24 publications receiving 3051 citations.
Papers
More filters
Journal ArticleDOI
Molecular Characterization of ALK, a Receptor Tyrosine Kinase Expressed Specifically in the Nervous System
Toshinori Iwahara,Jiro Fujimoto,Duanzhi Wen,Rod Cupples,Nathan Bucay,Tsutomu Arakawa,Shigeo Mori,Barry J. Ratzkin,Tadashi Yamamoto +8 more
TL;DR: Molecular cloning of cDNAs for both the human and mouse ALK proteins reveal that ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain and shows the greatest sequence similarity to LTK (leukocyte tyrosine Kinase) whose biological function is presently unknown.
Journal ArticleDOI
Expression of naphthalene oxidation genes in Escherichia coli results in the biosynthesis of indigo
Burt D. Ensley,Barry J. Ratzkin,Osslund Timothy D,Mary J. Simon,Lawrence P. Wackett,David T. Gibson +5 more
TL;DR: The results suggest that indigo formation is due to the combined activities of tryptophanase and naphthalene dioxygenase.
Journal ArticleDOI
Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK.
Chiaki Takahashi,Zeqi Sheng,Tom Horan,Hitoshi Kitayama,Masatoshi Maki,Kiyotaka Hitomi,Yasuyuki Kitaura,Setsuo Takai,Regina Maki Sasahara,Aki Horimoto,Yoji Ikawa,Barry J. Ratzkin,Tsutomu Arakawa,Makoto Noda +13 more
TL;DR: Restored expression of RECK in malignant cells resulted in suppression of invasive activity with concomitant decrease in the secretion of matrix metalloproteinase-9 (MMP-9), a key enzyme involved in tumor invasion and metastasis.
Journal ArticleDOI
Functional expression of cloned yeast DNA in Escherichia coli
Barry J. Ratzkin,John Carbon +1 more
TL;DR: Complementation of bacterial mutations by yeast DNA segments does not appear to be a rare phenomenon.
Journal ArticleDOI
Bivalence of EGF‐like ligands drives the ErbB signaling network
E Tzahar,Ronit Pinkas-Kramarski,James D. Moyer,Leah N. Klapper,Iris Alroy,Gil Levkowitz,Maya Shelly,Sivan Henis,Miriam Eisenstein,Barry J. Ratzkin,Michael Sela,Glenn C. Andrews,Yosef Yarden +12 more
TL;DR: Ligand bivalence enables signal diversification through selective recruitment of homo‐ and heterodimers of ErbB receptors, and it may explain oncogenicity of erbB‐2/HER2.